Generic Name and Formulations:
Rimabotulinumtoxin B 2500 Units/0.5mL, 5000 Units/1mL, 10000 Units/2mL; soln for IM inj; contains human albumin; preservative-free.
Indications for MYOBLOC:
Cervical dystonia, to reduce severity of abnormal head position and neck pain.
Should be administered and managed by experienced physicians. Individualize. Treatment-experienced: Initially 2500 to 5000 Units divided among affected muscles. Treatment-naïve: use lower initial dose. Adjust subsequent doses based on response.
Infection at proposed injection site.
Not interchangeable with other botulinum toxin products. Pre-existing dysphagia. Respiratory disorders. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Contains human albumin; monitor for possible viral disease transmission. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds). Concomitant other botulinum toxin products may potentiate neuromuscular paralysis.
Inj site reactions, dry mouth, dysphagia (may be severe), dyspepsia, headache, respiratory difficulties, allergic reactions (discontinue if occurs), spread of toxin effect (may be fatal).
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|